Keytruda marks the first perioperative anti-PD-1 treatment option for adults with PD-L1–positive resectable locally advanced ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

Approval of Zusduri was based on data from the Phase III ENVISION trial, which showed a 78% complete response at three months ...

The company focuses on specialty drugs and uses a combination of AI and human expertise to automate the process.

In that light, the GLP-1 rebound effect is not an obstacle but an opportunity to chart a new, holistic course in obesity care ...

Marvel Comics announced a new comic book starring a superhero that lives with type 1 diabetes. The project is being developed ...

Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus ...

Results from a first-in-human Phase Ia/Ib trial show that LY4170156 demonstrated a notably high overall response rate in ...

Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

Early Phase I results for JNJ-79635322 demonstrated an 86.1% overall response rate in heavily pretreated multiple myeloma ...